Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signature
Ieuan Walker(King's College London), Michael A. Chapman(Toronto Metropolitan University), Anna Aubareda(University of Cambridge), William Wilson(Cancer Research UK), Elizabeth H. Phillips(University of Manchester), Daria Galas‐Filipowicz(CRUK Lung Cancer Centre of Excellence), Evelyn Fitzsimons(CRUK Lung Cancer Centre of Excellence), James D. Cavenagh(National Health Service), Tushhar Dadaga(Cancer Research UK), Javier Herrero(London Cancer), Laura Clifton‐Hadley(Cancer Research UK), Kane Foster(London Cancer), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Venetia D’arcy(University of Cambridge), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Georgina S.F. Anderson(University of Cambridge), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Sumaiya Kamora(Cancer Research UK), Garima Khandelwal(Cancer Institute (WIA)), Ruth M. de Tute(St James's University Hospital), Selina J Chavda(University College London), Reuben Benjamin(King's College London)
Cited by 2
Related Papers
An integrated encyclopedia of DNA elements in the human genome
|Nature|2012|19.6k
An integrated encyclopedia of DNA elements in the human genome
|The Journal of the American Medical Association (JAMA) Network (American Medical Association)|2012|2.8k
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k